SNO 2020: In Recurrent GBM, the Immunotherapeutic MDNA55 May Extend Survival by >100%
The drug is delivered by convection enhanced delivery.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.